Ophthalmology · New York, NY
NPI
1770664294
Since 2006
Specialty
Ophthalmology
Code 207W00000X
Group practices
5
Medicare group memberships
Hospitals
0
Hospital affiliations
125 W 79th St
New York, NY, 10024
Phone (212) 785-1059
Groups this clinician bills Medicare through
Medicare paid, 2024
$54K
833 services
Medicare patients, 2024
141
Average age 76
Drug cost, 2024
$486K
2,055 prescriptions
Company payments, 2025
$2,972
From 13 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Raphael A Castillo was code 92134 (computerized ophthalmic imaging), 124 times for 63 patients. In total Raphael A Castillo billed 833 services in 37 codes, and Medicare paid $54K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2015-10-12.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 92134 Computerized Ophthalmic Imaging | Office | 124 | 63 | $33.38 | $4,139 |
| 92250 Angiography | Office | 93 | 75 | $28.98 | $2,695 |
| 92014 Ophthalmological E&M | Office | 88 | 64 | $100.49 | $8,843 |
| 76512 Ultrasound - Nonspecific | Office | 70 | 30 | $36.04 | $2,523 |
| 67028 Intravitreal Injection | Office | 67 | 21 | $96.27 | $6,450 |
| 92202 Ophthalmological E&M | Office | 67 | 58 | $12.48 | $836 |
| 92012 Ophthalmological E&M | Office | 65 | 50 | $69.88 | $4,542 |
| J9035 Injection, bevacizumab, 10 mg | Office | 62 | 20 | $53.31 | $3,305 |
| 92133 Computerized Ophthalmic Imaging | Office | 33 | 28 | $30.49 | $1,006 |
| 99213 Office E&M - Established | Office | 30 | 24 | $73.01 | $2,190 |
| 92083 Vision, Hearing, and Speech Services | Office | 22 | 21 | $56.75 | $1,249 |
| 99214 Office E&M - Established | Office | 21 | 21 | $113.89 | $2,392 |
| 92235 Angiography | Office | 20 | 19 | $144.16 | $2,883 |
By year: 2022 $71K for 1,016 services; 2023 $81K for 1,178 services; 2024 $54K for 833 services.
Medicare prescription drug claims, 2024
In 2024, the drug Raphael A Castillo prescribed most often to Medicare patients was Latanoprost, with 270 prescriptions and refills. In total Raphael A Castillo wrote 2,055 Medicare prescriptions that cost $486K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Latanoprost Generic | 270 | 508 | 135 | $2,209 |
| Azelastine Hcl Generic | 264 | 276 | 70 | $2,367 |
| Restasis Cyclosporine | 229 | 265 | 85 | $160K |
| Prednisolone Acetate Generic | 128 | 182 | 89 | $5,522 |
| Lumigan Bimatoprost | 112 | 193 | 44 | $50K |
| Bepotastine Besilate Generic | 102 | 138 | 34 | $17K |
| Brimonidine Tartrate Generic | 101 | 185 | 57 | $9,853 |
| Xiidra Lifitegrast | 84 | 112 | 39 | $72K |
| Ketorolac Tromethamine Generic | 71 | 88 | 55 | $1,436 |
| Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat | 70 | 128 | 40 | $1,120 |
| Timolol Maleate Generic | 66 | 164 | 31 | $820 |
| Combigan Brimonidine Tartrate/Timolol | 64 | 116 | 30 | $26K |
| Cyclosporine Generic | 58 | 75 | 24 | $16K |
| Neomycin-Polymyxin-Dexameth Neomycin/Polymyxin B/Dexametha | 41 | 43 | 31 | $394 |
| Ofloxacin Generic | 38 | 47 | 34 | $768 |
Brand drugs: 1,065 claims; generic drugs: 990 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Raphael A Castillo $2,972 ($2,972 in general payments such as food, travel and fees) from 13 companies. The largest payer was Bausch & Lomb Americas Inc. with $816.
| Company | Payments | Amount |
|---|---|---|
| Bausch & Lomb Americas Inc. BLCO | 10 | $816 |
| Alcon Vision LLC ALC | 13 | $499 |
| LENSAR, Inc. LNSR | 1 | $358 |
| Biotissue Holdings Inc. | 5 | $354 |
| Abbvie Inc. ABBV | 6 | $219 |
| Tarsus Pharmaceuticals, Inc. TARS | 4 | $215 |
| Rayner Intraocular Lenses Limited | 1 | $164 |
| RxSight Inc RXST | 1 | $147 |
| Amgen Inc. AMGN | 3 | $57.43 |
| Sun Pharmaceutical Industries Inc. SUNPHARMA.NS | 2 | $55.32 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.